Related Experiment Video
Updated: Mar 10, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
10.8K
Clinician Satisfaction With Pharmacogenomics Clinical Services at a Multistate Health System
Kristen Jacobsen1, Natasha J Petry1,2, Max Weaver1
1Sanford Imagenetics, Sanford Health, Sioux Falls, South Dakota, USA.
Clinical and Translational Science
|March 9, 2026
Summary
Clinician satisfaction with pharmacogenomics (PGx) services is high, particularly with pharmacist notes and decision support. While PGx positively impacts patient outcomes, explaining results to patients remains a challenge.
Area of Science:
- Clinical Pharmacology
- Genetics
- Health Services Research
Background:
- Pharmacogenomics (PGx) optimizes medication management using genetic information.
- Barriers to PGx implementation include limited clinician knowledge, time, and financial constraints.
- Limited data exists on clinician satisfaction with existing PGx clinical services.
Purpose of the Study:
- To assess clinician satisfaction with PGx services within a single health system.
- To identify specific domains of PGx services that contribute to clinician satisfaction.
- To understand clinician-reported impacts and barriers related to PGx implementation.
Main Methods:
- An internally developed survey was distributed to 645 clinicians who utilized PGx services within the past 3 years.
- Survey responses were collected in June 2025 from a total of 36 participating clinicians.
- Satisfaction was assessed across various clinical service domains, including ordering, EHR integration, and results return.
Main Results:
- Clinicians reported high satisfaction with most PGx clinical service domains, especially pharmacist notes and clinical decision support.
- Most respondents indicated that PGx results positively impacted patient outcomes.
- Nearly half of clinicians experienced barriers in explaining PGx results to patients, suggesting a role for PGx clinics.
Conclusions:
- Clinicians are generally satisfied with current PGx clinical services, highlighting the value of pharmacist support and decision support tools.
- Despite high satisfaction, challenges persist in communicating PGx results to patients.
- PGx clinics may offer a solution to mitigate barriers in patient result explanation, improving overall PGx utility.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
104
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
104
01:29Pharmacogenomics: Identification of New Drug Targets
57
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
57
01:27Pharmacogenetics of Drug Metabolism: Overview
77
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
77
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
80
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
80
01:27Principles of Pharmacogenetics: Types of Genetic Variants
68
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
68
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
81
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
81